Marcus Maurer, EAACI 2021: Avapritinib for Advanced Systemic Mastocytosis – The PATHFINDER Study

At EAACI 2021 touchIMMUNOLOGY has joined Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) to discuss the rationale behind avapritinib for advanced systemic mastocytosis and the results of the PATHFINDER study.

Questions

  1. Could you give us a brief overview of the disease burden of advanced systemic mastocytosis and the unmet needs in its treatment? (0:26)
  2. What was the rationale for investigating avapritinib in the treatment of patients with advanced systemic mastocytosis? (1:04)
  3. Could you tell us a little about the PATHFINDER study and its findings? (1:39)
  4. How clinically meaningful are these benefits? (2:35)


Link to the video: Marcus Maurer, EAACI 2021: Avapritinib for Advanced Systemic Mastocytosis - The PATHFINDER Study - touchIMMUNOLOGY

Filmed in coverage of the 2021 EAACI Annual Meeting.

Berlin, 21.09.2021 (GA2LEN UCARE Network). Burning, itching, pain - more than one percent of the world’s population suffers from chronic urticaria (hives) and the number is growing. Unfortunately, this disease still receives too little public attention. The GA²LEN UCARE Network, the Urticaria Network (UNEV) and the German Allergy and Asthma Association (DAAB) have therefore been initiating World...

Read more

Professor Maurer discusses chronic urticaria with Sarah Lepsy who runs multiple groups for patients with urticaria and has a message for patients that are feeling hopeless.

Read more

In this episode, our host is joined by Dr Ivan Chérrez Ojeda, an urticariologist and communication technology enthusiast, to discuss the potential application of telemedicine in the management of patients with chronic urticaria.

Link: https://www.medthority.com/csu-learning-zone/podcast-series/

Read more

Could targeting cytokines produced by autoreactive T cells benefit patients with chronic spontaneous urticaria (CSU)? Professor Marcus Maurer is joined by Professor Elias Toubi to discuss the role of T cells in CSU.

Link: https://www.medthority.com/csu-learning-zone/podcast-series/

Read more

At EAACI 2021 touchIMMUNOLOGY were delighted to talk with Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) to discuss the Phase 1a study of CDX-0159 in patients with chronic inducible urticaria.

Read more

The overall aim of this webinar is to improve the management and awareness of solar urticaria and its differential diagnoses by learning about the clinical spectrum of UV-light induced skin diseases

Read more

In this episode, Dr Young-Min Ye shares the findings of her cutting-edge research into predictors of remission in chronic urticaria, and explains what is currently known about the role of Mas-related G protein coupled receptor X2 (MRGPRX2) in the activation of mast cells.

Link: https://www.medthority.com/csu-learning-zone/podcast-series/

Read more

How do comorbidities affect patients with chronic spontaneous urticaria and what can be done to minimise their impact? Find out more on this crucial, yet understudied topic from our latest guest, Dr Simon Francis Thomsen.

www.medthority.com/csu-learning-zone/podcast-series/

Read more

In this episode, our host is joined by Dr Moshe Ben-Shoshan, who shares his pioneering approach to treating paediatric patients and draws on his experience to debunk some of the common myths surrounding childhood urticaria.

https://www.medthority.com/csu-learning-zone/podcast-series/

Read more

In this episode, our host is joined by UK-based dermatologist Dr Clive Grattan to address some of the most important unanswered questions in the field of chronic spontaneous urticaria.

LINK: www.medthority.com/csu-learning-zone/podcast-series/

Read more

Contact us

GA²LEN coordinating Office
c/o DGAKI
Robert-Koch-Platz 7
10115 Berlin, Germany

UCARE office
Laura Schwenner

info(at)ga2len-ucare.com